Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Interpore Cross introduces shareholder rights plan:

This article was originally published in Clinica

Executive Summary

Interpore Cross International has declared a dividend distribution of one preferred share purchase right for each outstanding share of common stock, which will be exercisable if a person or group acquires or offers to acquire more than 15% of the company's common stock. The previous shareholder rights plan terminated when Interpore International merged with Cross Medical Products in May (Clinica No 797, p11). Irvine, California-based Interpore Cross has also approved a repurchase programme for up to $4 million of its common stock, which will run until June 1999.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT082655

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel